Novartis announces update to company's Board of Directors to take effect in February 2013
NOVARTIS FINANCE S.A. /
Novartis announces update to company's Board of Directors to take effect in
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basel, November 9, 2012- Novartis announced today that Marjorie Yang has decided not to seek re-election to the Novartis Board of Directors at the Novartis Annual General Meeting in 2013. Ms. Yang joined the Novartis Board in 2007 and her current term is ending in 2013.
"We want to thank Ms. Yang for her important and valuable contributions as well as her dedication to Novartis," said Dr Daniel Vasella, Chairman of Novartis AG.
As customary, the company will provide shareholders with a list of proposals ahead of its Annual General Meeting scheduled for February 2013.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 127,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
# # #
Novartis Media Relations
|Central media line : +41 61 324 2200 |
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact: email@example.com.
Novartis Investor Relations
|Central phone:|| +41 61 324 7944 |
| Susanne Schaffert || +41 61 324 7944 ||North America:|
| Pierre-Michel Bringer || +41 61 324 1065 || Helen Boudreau || +1 212 830 2404 |
| Thomas Hungerbuehler || +41 61 324 8425 || Jill Pozarek || +1 212 830 2445 |
| Isabella Zinck || +41 61 324 7188 || Edwin Valeriano || +1 212 830 2456 |
| e-mail: firstname.lastname@example.org|| e-mail: email@example.com|
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: NOVARTIS FINANCE S.A. via Thomson Reuters ONE